PHAXIAM Therapeutics extends its phage portfolio 

• Klebsiella pneumoniae is responsible for severe infections and stands out for its high resistance to antibiotics
• PHAXIAM’s anti-Klebsiella pneumoniae phages to enter pre-clinical development to assess their efficacy in lung, blood and urinary tract infections, in addition to the three major targets already developed (S. aureus, P. aeruginosa, E. coli)

Lyon (France) and Cambridge (MA, US), September 19, 2023 – 07:00 a.m. CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the launch of a new preclinical development targeting a strong antimicrobial-resistant bacteria, Klebsiella pneumonia. Klebsiella pneumoniae (K. pneumoniae) causes a wide range of infections, including pneumonia, urinary tract infections, bacteremia and liver abscesses, and mainly infects immunocompromised people. However, the emergence and spread of hypervirulent and multi-resistant strains of this bacterium have recently extended its potential targets to people with no health problems.

READ THE PRESS RELEASE